Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
Tire Brands for Senior Drivers: Guaranteeing Security and Solace- The Magnificence of Extraordinariness: Presenting Valuable Adornments and Gemstones
- Why do people get headaches and migraines? A child neurologist explains the science of head pain and how to treat it
- Chicago reports first rabies-positive dog in 61 years. What we know.
- As infant botulism cases climb to 31, recalled ByHeart baby formula is still on some store shelves
- This Unique National Park In Canada Is Famous For Its Otherworldly Limestone Monoliths
- Shah Capital pushes for Novavax sale, warns of proxy fight
- ‘RuPaul's Drag Race’ Season 18: How to watch without cable, premiere time, cast list and more
- Can scientists detect life without knowing what it looks like? Research using machine learning offers a new way
